Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae
- PMID: 21041503
- PMCID: PMC3019638
- DOI: 10.1128/AAC.01198-10
Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae
Abstract
We evaluated the efficacy of NXL104, a novel β-lactamase inhibitor, in combination with ceftazidime (CAZ) in two murine infection models (septicemia and thigh infection). We chose two KPC-producing Klebsiella pneumoniae strains (VA-361 and VA-406) showing MICs of CAZ of ≥256 μg/ml. Septicemia was induced by the intraperitoneal injection of KPC-producing K. pneumoniae followed 30 min later by a single subcutaneous treatment with CAZ alone or CAZ-NXL104 in ratios of 2:1, 4:1, 8:1, and 16:1. In this model, the median effective doses for 50% (ED(50)) of the animals for CAZ alone versus VA-361 and VA-406 were 1,578 and 709 mg/kg of body weight, respectively. When combined with NXL104 at 2:1, 4:1, 8:1, and 16:1 ratios, the CAZ ED(50)s for VA-361 and VA-406 were reduced to 8.1 and 3.5 mg/kg, 15.1 and 3.8 mg/kg, 16.9 and 7.2 mg/kg, and 29.5 and 12.1 mg/kg, respectively. For thigh infection, neutropenia was induced by the intraperitoneal injection of cyclophosphamide at days -4 and -1 preinfection. Infection was established by the intramuscular injection of KPC-producing K. pneumoniae into the right thigh. Mice were treated 1.5 h postinfection with either CAZ alone or CAZ-NXL104 at constant ratios of 4:1. When thighs were removed at 24 h postinfection, a >2-log CFU reduction was observed for mice treated with CAZ-NXL104 at doses of ≥128:32 mg/kg. In contrast, CAZ doses of ≥1,024 mg/kg were unable to reduce the numbers of CFU. Despite resistance to CAZ and possessing a complex β-lactamase background, NXL104 combined with CAZ proved to be very effective in murine models of infection due to contemporary highly resistant KPC-producing K. pneumoniae isolates.
Figures
Similar articles
-
Efficacy of ceftazidime-avibactam in various combinations for the treatment of experimental osteomyelitis due to Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae.Int J Antimicrob Agents. 2023 Jan;61(1):106702. doi: 10.1016/j.ijantimicag.2022.106702. Epub 2022 Dec 5. Int J Antimicrob Agents. 2023. PMID: 36476965
-
Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by Klebsiella pneumoniae Carbapenemase-producing K. pneumoniae.Clin Infect Dis. 2019 Jan 18;68(3):355-364. doi: 10.1093/cid/ciy492. Clin Infect Dis. 2019. PMID: 29893802
-
Ceftazidime-Avibactam Use for Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae Infections: A Retrospective Observational Multicenter Study.Clin Infect Dis. 2021 Nov 2;73(9):1664-1676. doi: 10.1093/cid/ciab176. Clin Infect Dis. 2021. PMID: 33618353
-
The antibiotic arms race: current and emerging therapy for Klebsiella pneumoniae carbapenemase (KPC) - producing bacteria.Expert Opin Pharmacother. 2018 Dec;19(18):2019-2031. doi: 10.1080/14656566.2018.1538354. Epub 2018 Nov 5. Expert Opin Pharmacother. 2018. PMID: 30346216 Review.
-
Use of carbapenems in the combined treatment of emerging ceftazidime/avibactam-resistant and carbapenem-susceptible KPC-producing Klebsiella pneumoniae infections: Report of a case and review of the literature.J Glob Antimicrob Resist. 2020 Sep;22:9-12. doi: 10.1016/j.jgar.2019.11.007. Epub 2019 Nov 13. J Glob Antimicrob Resist. 2020. PMID: 31733412 Review.
Cited by
-
Reclaiming the efficacy of β-lactam-β-lactamase inhibitor combinations: avibactam restores the susceptibility of CMY-2-producing Escherichia coli to ceftazidime.Antimicrob Agents Chemother. 2014 Aug;58(8):4290-7. doi: 10.1128/AAC.02625-14. Epub 2014 May 12. Antimicrob Agents Chemother. 2014. PMID: 24820081 Free PMC article.
-
Evaluating the Efficacies of Carbapenem/β-Lactamase Inhibitors Against Carbapenem-Resistant Gram-Negative Bacteria in vitro and in vivo.Front Microbiol. 2019 Apr 30;10:933. doi: 10.3389/fmicb.2019.00933. eCollection 2019. Front Microbiol. 2019. PMID: 31114565 Free PMC article.
-
The Epidemiology, Evolution, and Treatment of KPC-Producing Organisms.Curr Infect Dis Rep. 2018 May 5;20(6):13. doi: 10.1007/s11908-018-0617-x. Curr Infect Dis Rep. 2018. PMID: 29730830 Review.
-
Pharmacokinetics and penetration of ceftazidime and avibactam into epithelial lining fluid in thigh- and lung-infected mice.Antimicrob Agents Chemother. 2015 Apr;59(4):2299-304. doi: 10.1128/AAC.04627-14. Epub 2015 Feb 2. Antimicrob Agents Chemother. 2015. PMID: 25645843 Free PMC article.
-
10 x '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America.Clin Infect Dis. 2013 Jun;56(12):1685-94. doi: 10.1093/cid/cit152. Epub 2013 Apr 17. Clin Infect Dis. 2013. PMID: 23599308 Free PMC article.
References
-
- Curiao, T., M. I. Morosini, P. Ruiz-Garbajosa, A. Robustillo, F. Baquero, T. M. Coque, and R. Canton. 2010. Emergence of bla KPC-3-Tn4401a associated with a pKPN3/4-like plasmid within ST384 and ST388 Klebsiella pneumoniae clones in Spain. J. Antimicrob. Chemother. 65:1608-1614. - PubMed
-
- Endimiani, A., A. M. Hujer, F. Perez, C. R. Bethel, K. M. Hujer, J. Kroeger, M. Oethinger, D. L. Paterson, M. D. Adams, M. R. Jacobs, D. J. Diekema, G. S. Hall, S. G. Jenkins, L. B. Rice, F. C. Tenover, and R. A. Bonomo. 2009. Characterization of blaKPC-containing Klebsiella pneumoniae isolates detected in different institutions in the Eastern USA. J. Antimicrob. Chemother. 63:427-437. - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases